gyki 52466 and ergoline

gyki 52466 has been researched along with ergoline in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Schmidt, WJ; Zadow, B	1

Other Studies

1 other study(ies) available for gyki 52466 and ergoline

Article	Year
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn-Schmiedeberg's archives of pharmacology, 1994, Volume: 349, Issue:1 Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA	1994

Article

Year

The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.

Naunyn-Schmiedeberg's archives of pharmacology, 1994, Volume: 349, Issue:1

Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA

1994